NPHC has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NPHC has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
The Cash Ratio measures a company’s ability to meet its short-term obligations with cash and near-cash resources. It is calculated as a company's Cash, Cash Equivalents, Marketable Securities divides by its Total Current Liabilities. Nutra Pharma's Cash Ratio for the quarter that ended in Sep. 2022 was 0.00.
Nutra Pharma has a Cash Ratio of 0.00. It indicates that there are more current liabilities than Cash, Cash Equivalents, Marketable Securities, and the company does not have sufficient cash on hand to pay off its short-term debt.
The historical rank and industry rank for Nutra Pharma's Cash Ratio or its related term are showing as below:
The historical data trend for Nutra Pharma's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nutra Pharma Annual Data | |||||||||||||||||||||
Trend | Dec12 | Dec13 | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | |||||||||||
Cash Ratio | Get a 7-Day Free Trial | - | - | - | - | - |
Nutra Pharma Quarterly Data | ||||||||||||||||||||
Dec17 | Mar18 | Jun18 | Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | |
Cash Ratio | Get a 7-Day Free Trial | - | - | - | - | - |
For the Drug Manufacturers - Specialty & Generic subindustry, Nutra Pharma's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, Nutra Pharma's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Nutra Pharma's Cash Ratio falls into.
The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.
Nutra Pharma's Cash Ratio for the fiscal year that ended in Dec. 2021 is calculated as:
Cash Ratio (A: Dec. 2021 ) | = | Cash, Cash Equivalents, Marketable Securities | / | Total Current Liabilities |
= | 0.091 | / | 21.14 | |
= | 0.00 |
Nutra Pharma's Cash Ratio for the quarter that ended in Sep. 2022 is calculated as:
Cash Ratio (Q: Sep. 2022 ) | = | Cash, Cash Equivalents, Marketable Securities | / | Total Current Liabilities |
= | 0 | / | 16.148 | |
= | 0.00 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nutra Pharma (OTCPK:NPHC) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Thank you for viewing the detailed overview of Nutra Pharma's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Rik J Deitsch | officer: Chief Executive Officer | 4001 NW 73 WAY, CORAL SPRINGS FL 33065 |
Dan Oran | director | 8411 W OAKLAND PARK BLVD, #201, SUNRISE FL 33351 |
Bruno Sartori | other: Former CFO | 275 COMMERCIAL BLVD, STE 260, FT LAUDERDALE FL 33308 |
Harold Henry Rumph | director, officer: President - ReceptoPharm | 1537 N.W. 65TH AVENUE, PLANTATION FL 33313 |
David Michael Isserman | officer: Chief Marketing Officer | 2776 UNIVERSITY DRIVE, CORAL SPRINGS FL 33065 |
Garry Pottruck | director | 10768 NW 18TH CT, CORAL SPRINGS FL 33071 |
Paul F Reid | director | 9610 NW 24 CT, SUNRISE FL 33322 |
Michael Doherty | director, officer: Executive Chairman | |
Tanvir A Khandaker | director | 387 PARK AVENUE SOUTH THIRD FLOOR, NEW YORK NY 10016 |
Stewart Alan Lonky | director | 1158 CHAUTAUQUA BLVD., PACIFIC PALISADES CA 90272 |
Stanley Jack Cherelstein | director | 2401 SW MANOR HILL DRIVE, PALM CITY FL 34990 |
Michael Flax | director, officer: Chief Financial Officer | 2499 BANYAN RD, BOCA RATON FL 33432 |
Mcclelland David C Sr | director | P.O. BOX 263, FINDLEY LAKE NY 14736 |
Mitchell S Felder | director | PO BOX 1332, HERMITAGE PA 16148 |
Khalsa Soram Singh Md | director | 436 N BEDFORD DR, BEVERLY HILLS CA 90210 |
From GuruFocus
By Marketwired Marketwired • 04-19-2018
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.